Ultragenyx Pharmaceutical Inc.

NASDAQ:RARE

Biotechnology

Healthcare
$17.22 +3.01%

+$0.81 today

Market cap
$1.76B
Beta
0.38
P/E (TTM)
-4.6
EPS (TTM)
-$6.06
52W Low $18.29High $42.37

Volume 3.12M

Average 1.81M

Income Statement

Follow revenue through to earnings.

Revenue

$673.00M

FY 2025 · Annual

+20.1% YoY

Operating Income

-$535.00M

FY 2025 · Annual

Net Income

-$575.00M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue351.41M363.33M434.25M560.23M673M
Cost of Revenue16.01M28.32M45.21M76.73M109M
Gross Profit335.4M335.01M389.04M483.5M564M
Gross Margin95.4%92.2%89.6%86.3%83.8%
Research & Development497.15M705.79M648.45M697.87M750M
Selling, General & Admin219.98M278.14M309.8M321.61M349M
Operating Expenses717.14M983.93M958.25M1.02B1.1B
Depreciation & Amortization13.24M18.22M26.01M35.54M35M
EBITDA(410.32M)(640.49M)(516.45M)(469M)(474M)
EBITDA Margin-116.8%-176.3%-118.9%-83.7%-70.4%
Operating Income(381.74M)(648.92M)(569.21M)(535.97M)(535M)
Operating Margin-108.6%-178.6%-131.1%-95.7%-79.5%
Interest Income1.93M11.07M26.69M36.51M25M
Interest Expense29.42M43.02M66M63.04M62M
Other Income / Expenses(71.24M)(52.81M)(39.26M)(31.61M)(36M)
Income Before Tax(452.98M)(701.73M)(608.46M)(567.59M)(571M)
Pre-Tax Margin-128.9%-193.1%-140.1%-101.3%-84.8%
Income Tax Expense1.04M5.7M(1.83M)1.6M4M
Net Income(454.03M)(707.42M)(606.64M)(569.18M)(575M)
Net Margin-129.2%-194.7%-139.7%-101.6%-85.4%
EPS (Basic)(6.70)(10.12)(8.25)(6.29)(5.83)
EPS (Diluted)(6.70)(10.12)(8.25)(6.29)(5.83)
Weighted Avg Shares67.8M69.91M73.54M90.54M98.6M
Weighted Avg Shares (Diluted)67.8M69.91M73.54M90.54M98.6M

RARE Earnings Waterfall · TTM

NASDAQ:RARE · Revenue to Net Income

Key Ratios

EPS$-6.11
Gross Margin83.2%
Net Margin-95.0%
P/E Ratio-4.8
P/S Ratio16.7

Analysis

$669.4M of revenue converted into -$609.4M of net income for the selected period. Gross margin is 83.2% and net margin is -95.0%, showing how much revenue survives after costs and taxes. EPS is $-6.11, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 13, 2026
SC 13GSC 13G filingNov 10, 2026
10-QQuarterly reportNov 4, 2026
8-KCurrent reportNov 3, 2026
SC 13G/ASC 13G/A filingOct 30, 2026

How much revenue does RARE generate?

Ultragenyx Pharmaceutical Inc. (RARE) reported $673.00M of revenue in fiscal 2025.

Is RARE profitable?

Ultragenyx Pharmaceutical Inc. (RARE) reported -$575.00M of net income, with a net margin of -85.4%.